Tilo Biedermann1, Piotr Kuna2, Petr Panzner3, Erkka Valovirta4, Morgan Andersson5, Frederic de Blay6, Dorthe Thrane7, Sanja Hald Jacobsen7, Brian Sonne Stage7, Lone Winther8. 1. Department of Dermatology and Allergology, Technical University of Munich, Munich, Germany. Electronic address: tilo.biedermann@tum.de. 2. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland. 3. Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic. 4. Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland; Terveystalo Allergy Clinic, Turku, Finland. 5. Department of Otorhinolaryngology, Head and Neck Surgery, Skåne University Hospital, Lund, Sweden. 6. Federation of Translational Medicine Chest Disease Department, University Hospital of Strasbourg, University of Strasbourg, Strasbourg, France. 7. Global Clinical Development, ALK-Abelló, Hørsholm, Denmark. 8. Allergy Clinic, Department of Dermato-Allergology, Gentofte Hospital, Copenhagen, Denmark.
Abstract
BACKGROUND: The SQ tree sublingual immunotherapy (SLIT)-tablet (ALK-Abelló, Hørsholm, Denmark) is developed for treatment of tree pollen-induced allergic rhinoconjunctivitis (ARC). OBJECTIVE: The aim of this pivotal phase III trial was to demonstrate the efficacy and safety of the SQ tree SLIT-tablet. METHODS: This was a randomized, double-blind, placebo-controlled trial with 634 subjects (12-65 years) with moderate-to-severe ARC despite use of symptom-relieving medication. Eligible subjects were randomized 1:1 to active or placebo treatment. The primary end point was the average daily ARC total combined score (TCS) during the birch pollen season (BPS) analyzed for subjects with diary data during the BPS. Secondary end points included average daily symptom scores (DSS) during the BPS, average TCS and DSS during the tree pollen season (TPS), and average daily medication scores (DMS) in the BPS and TPS. RESULTS: The primary and key secondary end points demonstrated statistically significant and clinically relevant effects of the SQ tree SLIT-tablet compared with placebo. For the BPS, absolute (relative) differences from placebo were 3.02 (40%) for TCS, 1.32 (37%) for DSS, and 1.58 (49%) for DMS (all P < .0001). For the TPS, absolute (relative) differences from placebo were 2.27 (37%) for TCS, 0.99 (33%) for DSS, and 1.20 (47%) for DMS (all P < .0001). Treatment was well tolerated. The most frequently reported treatment-related adverse events were mild or moderate local reactions related to sublingual administration. CONCLUSION: The trial demonstrated the efficacy and safety of the SQ tree SLIT-tablet compared with placebo during the BPS and TPS in adolescents and adults with birch pollen-induced ARC (EudraCT 2015-004821-15).
RCT Entities:
BACKGROUND: The SQ tree sublingual immunotherapy (SLIT)-tablet (ALK-Abelló, Hørsholm, Denmark) is developed for treatment of tree pollen-induced allergic rhinoconjunctivitis (ARC). OBJECTIVE: The aim of this pivotal phase III trial was to demonstrate the efficacy and safety of the SQ tree SLIT-tablet. METHODS: This was a randomized, double-blind, placebo-controlled trial with 634 subjects (12-65 years) with moderate-to-severe ARC despite use of symptom-relieving medication. Eligible subjects were randomized 1:1 to active or placebo treatment. The primary end point was the average daily ARC total combined score (TCS) during the birch pollen season (BPS) analyzed for subjects with diary data during the BPS. Secondary end points included average daily symptom scores (DSS) during the BPS, average TCS and DSS during the tree pollen season (TPS), and average daily medication scores (DMS) in the BPS and TPS. RESULTS: The primary and key secondary end points demonstrated statistically significant and clinically relevant effects of the SQ tree SLIT-tablet compared with placebo. For the BPS, absolute (relative) differences from placebo were 3.02 (40%) for TCS, 1.32 (37%) for DSS, and 1.58 (49%) for DMS (all P < .0001). For the TPS, absolute (relative) differences from placebo were 2.27 (37%) for TCS, 0.99 (33%) for DSS, and 1.20 (47%) for DMS (all P < .0001). Treatment was well tolerated. The most frequently reported treatment-related adverse events were mild or moderate local reactions related to sublingual administration. CONCLUSION: The trial demonstrated the efficacy and safety of the SQ tree SLIT-tablet compared with placebo during the BPS and TPS in adolescents and adults with birch pollen-induced ARC (EudraCT 2015-004821-15).
Authors: Oliver Pfaar; Tobias Ankermann; Matthias Augustin; Petra Bubel; Sebastian Böing; Randolf Brehler; Peter A Eng; Peter J Fischer; Michael Gerstlauer; Eckard Hamelmann; Thilo Jakob; Jörg Kleine-Tebbe; Matthias Volkmar Kopp; Susanne Lau; Norbert Mülleneisen; Christoph Müller; Katja Nemat; Wolfgang Pfützner; Joachim Saloga; Klaus Strömer; Peter Schmid-Grendelmeier; Antje Schuster; Gunter Johannes Sturm; Christian Taube; Zsolt Szépfalusi; Christian Vogelberg; Martin Wagenmann; Wolfgang Wehrmann; Thomas Werfel; Stefan Wöhrl; Margitta Worm; Bettina Wedi; Susanne Kaul; Vera Mahler; Anja Schwalfenberg Journal: Allergol Select Date: 2022-09-06
Authors: Benedikt Fritzsching; Marco Contoli; Celeste Porsbjerg; Sarah Buchs; Julie Rask Larsen; Lisa Elliott; Mercedes Romano Rodriguez; Nick Freemantle Journal: Lancet Reg Health Eur Date: 2021-11-30
Authors: Letty A de Weger; Peter Th W van Hal; Bernadette Bos; Frank Molster; Marijke Mostert; Pieter S Hiemstra Journal: Front Allergy Date: 2021-04-08
Authors: Michael S Blaiss; Ruta Gronskyte Juhl; Leonard Q C Siew; Eva Hammerby; Philippe Devillier Journal: Allergy Date: 2022-01-22 Impact factor: 14.710
Authors: B Nothegger; N Reider; C E Covaciu; V Cova; L Ahammer; R Eidelpes; J Unterhauser; S Platzgummer; M Tollinger; T Letschka; K Eisendle Journal: J Eur Acad Dermatol Venereol Date: 2020-02-16 Impact factor: 6.166